CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

August 21, 2019 admin Healthcare, Investor Presentations Comments Off on CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

CytoDyn, Inc. (OTC: CYDY)

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Next Super Stock investor conference presentation 8/15/2019




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

April 30, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, Apr 30, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

February 14, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]